Clinical Trials Logo

Gastroparesis clinical trials

View clinical trials related to Gastroparesis.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03128398 No longer available - Gastroparesis Clinical Trials

Use of Domperidone for Treatment of Upper Gastrointestinal Disorders

Domperidone
Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access to Investigational Drug program available through the FDA. Some specific conditions to qualify for this program includes gastroesophageal reflux disease with upper GI symptoms, gastroparesis, and chronic constipation. Patients failing standard therapies for these conditions may be eligible to receive domperidone. This program facilitates availability of investigational drugs, (such as domperidone) to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor or treat the patients's disease or condition. Authorization must be obtained from FDA prior to the importation, interstate shipment and administration of domperidone.

NCT ID: NCT02757534 No longer available - Gastroparesis Clinical Trials

Domperidone for Chronic Nausea and Vomiting

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide oral domperidone to patients with gastroparesis, between the ages of 18 and 60 years of age, who have failed standard treatment. Standard therapy at the University of Iowa is eating blended foods, liquid diet, Eryped syrup (125 mg TID) 30 minutes before meals, or reglan (20 mg BID).